Bristol-Myers Squibb (BMY) Free Cash Flow (2008 - 2026)
Bristol-Myers Squibb (BMY) free cash flow from Jun 30, 2008 to Mar 31, 2026. The TTM Bristol-Myers Squibb (BMY) free cash flow is $12B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Free Cash Flow
Quarterly Free Cash Flow
Bristol-Myers Squibb (BMY) Free Cash Flow CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -9.00% |
| 3 Years TTM | +2.43% |
| 5 Years TTM | -2.10% |
| All Time TTM | +10.89% |
Annual Free Cash Flow change of Bristol-Myers Squibb (BMY)
| Year | Free Cash Flow | Change |
|---|---|---|
| 2026 | $757M | -94.11% |
| 2025 | $13B | -7.87% |
| 2024 | $14B | +10.20% |
| 2023 | $13B | +5.88% |
| 2022 | $12B | -21.57% |
| 2021 | $15B | +14.55% |
| 2020 | $13B | +83.92% |
| 2019 | $7.23B | +44.94% |
| 2018 | $4.99B | +18.22% |
| 2017 | $4.22B | +158.10% |
| 2016 | $1.64B | +61.56% |
| 2015 | $1.01B | -61.40% |
| 2014 | $2.62B | -12.83% |
| 2013 | $3.01B | -52.95% |
| 2012 | $6.39B | +42.92% |
| 2011 | $4.47B | +9.98% |
| 2010 | $4.07B | +21.95% |
| 2009 | $3.33B | +20.57% |
| 2008 | $2.77B | N/A |
Comparison Bristol-Myers Squibb (BMY) five years free cash flow CAGR with competitors
Bristol-Myers Squibb (BMY) five years free cash flow CAGR is -2.10%.
| Ticker | Name | five years Free Cash Flow CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 21.25% | -1111.35% |
| AZN | Astrazeneca plc | 15.68% | -846.20% |
| NVS | Novartis AG | 9.71% | -562.09% |
| SNY | Sanofi | 8.08% | -484.73% |
| MRK | Merck & Co Inc | 5.49% | -361.27% |
| GILD | Gilead Sciences Inc | 3.30% | -256.94% |
| ABBV | Abbvie Inc | 2.35% | -211.85% |